Stay informed on the latest Truth Social posts from Donald Trump (@realDonaldTrump) without the doomscrolling. Consider it a public service for your mental health. (Why?)
Filtering by entity: AstraZeneca | Clear Filter
Summary:The White House, under Donald Trump, has issued a directive to AstraZeneca and all drug manufacturers to implement Most-Favored-Nation (MFN) drug pricing for American patients, aiming to stop other nations from "freeloading" on American innovation and to lower prescription drug costs significantly by September 29, 2025.
Sentiment:Directive/Demanding
Key Claims:
- Americans currently pay up to three times more for identical prescription drugs than patients in other developed nations.
- Other nations are "freeloading" on American innovation in drug development.
- An Executive Order on "Most-Favored-Nation Prescription Drug Pricing" was signed on May 12, 2025.
- Drug manufacturers are called upon to extend MFN pricing to Medicaid, guarantee MFN pricing for newly-launched drugs, return increased revenues from abroad to American patients, and offer direct purchasing at MFN prices.
- The Administration is prepared to use every tool to protect Americans from abusive drug pricing practices if cooperation is not met.
- Binding commitments for these goals are expected by September 29, 2025.
Potential Market Impact (S&P 500):8/10
Potential Geopolitical Risk:0/10
Potential Global Cross-Asset Impact:7/10
« Previous
Page 1 of 1
Next »